Krebs Biochemicals & Industries has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Thursday, May 21, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda of the meeting is to consider and adopt the audited financial results for the 4th quarter and financial year ended March 31, 2026.

Board Meeting Details

The intimation was filed on May 7, 2026, by Rakesh R Kalbate, Company Secretary & Compliance Officer of Krebs Biochemicals and Industries Limited. The following table summarises the key details of the scheduled board meeting:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company had previously communicated via a letter dated March 19, 2026, that the trading window for dealing in the securities of the company by insiders would remain closed. The closure came into effect from the end of business hours on March 31, 2026, and will continue until 48 hours after the declaration of the company's audited financial results for the 4th quarter and financial year ended March 31, 2026.

Key highlights of the trading window closure are as follows:

• Closure effective from: End of business hours on March 31, 2026
• Closure applicable to: Insiders as defined under SEBI (Prohibition of Insider Trading) Regulations, 2015
• Window reopens: 48 hours after declaration of audited financial results
• Prior intimation date: March 19, 2026

The board meeting notification was duly submitted to both BSE Limited and the National Stock Exchange of India Ltd, fulfilling the company's disclosure obligations under applicable SEBI regulations.

Krebs Biochemicals & Industries Limited has issued a clarification to BSE Limited regarding significant movement in its share price, stating that no material events warrant disclosure under regulatory requirements.

Regulatory Inquiry Response

The company responded to BSE's inquiry dated April 8, 2026, which sought clarification on the notable price movement in the company's securities. The exchange's communication, bearing reference number L/SURV/ONL/PV/APJ/2026-2027/3564, prompted the company to provide an official statement on April 10, 2026.

Company's Official Statement

In its clarification, Krebs Biochemicals & Industries Limited explicitly stated that there are no material information or material events that required disclosure or announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized that, in its opinion, no undisclosed developments have influenced the recent price movement in its securities.

Compliance Commitment

The company reaffirmed its commitment to regulatory compliance, noting that it has been regularly disseminating relevant information and details whenever required. This practice aligns with the company's obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The clarification was signed by Rakesh R Kalbate, Company Secretary & Compliance Officer, demonstrating the company's formal approach to addressing regulatory inquiries and maintaining transparency with market participants and stakeholders.